Orphan Drugs in Germany – lessons learned from AMNOG, best and worst practices and strategic implications
Pharmaceutical companies planning to introduce new orphan drugs into the German market should prepare well in advance a sound and stringent strategy to optimize the performance throughout the entire market access processes. Please click here to read SKC's white paper which elaborates on all relevant issues and describes important recommendations for manufacturers facing these challenges.